Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CAI:PHAR'
s Net Margin % Range Over the Past 10 Years
Min: 14.24 Med: 18.29 Max: 27.26
Current: 14.24
CAI:PHAR's Net Margin % is ranked better than 76.72% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs CAI:PHAR: 14.24
Egyptian International Pharmaceutical Investments (CAI:PHAR) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Egyptian International Pharmaceutical Investments Net Margin % Related Terms
Egyptian International Pharmaceutical Investments Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments Net Margin % Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments Net Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Net Margin % of 11.21% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is 39% below median its historical median of 18.29. Over the past decade, Egyptian International Pharmaceutical Investments' Net Margin % has ranged from 14.24 to 27.26. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #224 out of 962 companies in the Drug Manufacturers industry, placing it in the top 23.3%.
Is Egyptian International Pharmaceutical Investments' Net Margin % too high?
Egyptian International Pharmaceutical Investments' current Net Margin % of 11.21% is 39% below median its 10-year median of 18.29. Over the past 10 years, this metric has ranged from a low of 14.24 to a high of 27.26. The Drug Manufacturers industry median Net Margin % is 5.56. Egyptian International Pharmaceutical Investments' value of 11.21% is 101.6% above this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #224 out of 962 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #224 out of 962 companies for Net Margin %. This places Egyptian International Pharmaceutical Investments in the top 23% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Egyptian International Pharmaceutical Investments' value of 11.21% is 101.6% above this benchmark. Historically, Egyptian International Pharmaceutical Investments' own Net Margin % has ranged from 14.24 to 27.26 over the past decade. While the company's 10-year median is 18.29 vs. the industry median of 5.56, Egyptian International Pharmaceutical Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current Net Margin % of 11.21% is 101.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current Net Margin % is 11.21%, which is 39% below median its own 10-year median of 18.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.81, compared to a current price of E£86.07 — trading 43.9% above its estimated fair value. The current Net Margin % is 11.21%, which is 39% below median its 10-year median of 18.29 and 101.6% above the Drug Manufacturers industry median of 5.56. Egyptian International Pharmaceutical Investments' overall GF Score™ is 70/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Net Margin % is 11.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£86.07 is trading 43.9% above its estimated GF Value™ of E£59.81.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
Net Margin %: 11.21% (39% below median its 10-year median of 18.29)
GF Value™: E£59.81 vs. price of E£86.07 (43.9% above fair value)
Industry Position: 101.6% above the Drug Manufacturers median (#224 of 962)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
70GF Score
Get the complete analysis for CAI:PHAR
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
